摘要
目的:观察全血灌流免疫吸附治疗兔实验性自身免疫性重症肌无力的疗效。方法:以电鳗乙酰胆碱受体α亚单位Ta125￣147段多肽为免疫源建立实验性自身免疫性重症肌无力动物模型,以球形纤维素为载体色氨酸为配基的吸附剂(IM-MG)进行全血灌流吸附治疗,观察治疗前后临床症状评分、抗体滴度及3,5,10Hz刺激频率下单纤维肌电图(SFEMG)腓肠肌平均连续波间值差异(MCD)的变化。结果:灌流2h,抗体最大吸附率为(50.73±7.67)%。临床无力症状相应改善,SFEMG示腓肠肌MCD从(23.00±4.14)μs(3Hz)、(28.00±4.07)μs(5Hz)和(30.88±5.06)μs(10Hz)明显地减少到(16.38±3.34)μs、(19.25±4.13)μs和(22.38±5.26)μs(均P<0.05)。结论:IM-MG全血灌流吸附治疗可能会成为重症肌无力的新型治疗方法。
Objective： To investigate the efficacy of systemic hemoperfusion adsorption in rabbit with experimental autoimmune myasthenia gravis （EAMG）. Methods： EAMG models in rabbits were produced by immunization with Ta125-147, which is a subunit of acetylcholine receptor of Torpedo Californica. The rabbits were then treated with systemic hemoperfusion with cellulose-tryptophan resin（IM-MG）. The clinical improvement was evaluated with clinical scores, antibody titers, and single fibre electromyography （SFEMG）. Results： The maximal removal of antibodies to Ta125-147 was （50.73±7.67）% in 2 h after treatment, with improvement in clinical neuromuscular function. SFEMG showed the mean consecutive difference （MCD,μs） in gastrocnemius dropped down after therapy,from 23.00±4.14（3 Hz）, 28.00±4.07 （5 Hz）and 30.88±5.06（10 Hz）to 16.38± 3.34（P 〈 0.05 ）, 19.25±4.13 （P 〈 0.05 ）and 22.38±5.26（P 〈 0.05 ）. Conclusion： Systemic hemoperfusion adsorption with IMMG could remove pathogenic antibodies in EAMG effectively, and improve clinical manifestation and neuromuscular function.
出处
《天津医药》
CAS
北大核心
2006年第5期324-326,共3页
Tianjin Medical Journal
